Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. by Reynès, Christelle et al.
Designing focused chemical libraries enriched in
protein-protein interaction inhibitors using
machine-learning methods.
Christelle Reyne`s, He´le`ne Host, Anne-Claude Camproux, Guillaume Laconde,
Florence Leroux, Anne Mazars, Benoit Deprez, Robin Fahraeus, Bruno
Villoutreix, Olivier Sperandio
To cite this version:
Christelle Reyne`s, He´le`ne Host, Anne-Claude Camproux, Guillaume Laconde, Florence Leroux,
et al.. Designing focused chemical libraries enriched in protein-protein interaction inhibitors
using machine-learning methods.. PLoS Computational Biology, Public Library of Science,
2010, 6 (3), pp.e1000695. <10.1371/journal.pcbi.1000695>. <inserm-00705646>
HAL Id: inserm-00705646
http://www.hal.inserm.fr/inserm-00705646
Submitted on 8 Jun 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Designing Focused Chemical Libraries Enriched in
Protein-Protein Interaction Inhibitors using
Machine-Learning Methods
Christelle Reyne`s1, He´le`ne Host2,3,4, Anne-Claude Camproux1, Guillaume Laconde2,3,4, Florence
Leroux2,3,4, Anne Mazars2,5, Benoit Deprez2,3,4, Robin Fahraeus2,5, Bruno O. Villoutreix1,2, Olivier
Sperandio1,2*
1 Inserm UMR-S 973/MTi, University Paris Diderot, Paris, France, 2CDithem Platform/IGM, Paris, France, 3 Inserm UMR-S 761, Institut Pasteur de Lille, Lille, France,
4Universite´ Lille 2, Faculte´ des Sciences Pharmaceutiques et Biologiques, Lille, France, 5UMR-S940, Hoˆpital St Louis, Paris, France
Abstract
Protein-protein interactions (PPIs) may represent one of the next major classes of therapeutic targets. So far, only a minute
fraction of the estimated 650,000 PPIs that comprise the human interactome are known with a tiny number of complexes
being drugged. Such intricate biological systems cannot be cost-efficiently tackled using conventional high-throughput
screening methods. Rather, time has come for designing new strategies that will maximize the chance for hit identification
through a rationalization of the PPI inhibitor chemical space and the design of PPI-focused compound libraries (global or
target-specific). Here, we train machine-learning-based models, mainly decision trees, using a dataset of known PPI inhibitors
and of regular drugs in order to determine a global physico-chemical profile for putative PPI inhibitors. This statistical analysis
unravels two important molecular descriptors for PPI inhibitors characterizing specific molecular shapes and the presence of a
privileged number of aromatic bonds. The best model has been transposed into a computer program, PPI-HitProfiler, that can
output from any drug-like compound collection a focused chemical library enriched in putative PPI inhibitors. Our PPI inhibitor
profiler is challenged on the experimental screening results of 11 different PPIs among which the p53/MDM2 interaction
screened within our own CDithem platform, that in addition to the validation of our concept led to the identification of 4 novel
p53/MDM2 inhibitors. Collectively, our tool shows a robust behavior on the 11 experimental datasets by correctly profiling
70% of the experimentally identified hits while removing 52% of the inactive compounds from the initial compound
collections. We strongly believe that this new tool can be used as a global PPI inhibitor profiler prior to screening assays to
reduce the size of the compound collections to be experimentally screened while keeping most of the true PPI inhibitors. PPI-
HitProfiler is freely available on request from our CDithem platform website, www.CDithem.com.
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Introduction
Protein-protein interactions regulate most aspects of Life and
mapping these networks is nowadays one of the most difficult
challenges in molecular medicine and biology. Aberrant PPIs
contribute to most disease states and therefore represents a highly
populated class of essentially untouched targets for drug discovery.
While all PPIs may not be modulated by small drug-like
compounds, among the about 650,000 interactions that regulate
human life [1], a sizable number should be druggable [2–7], as
suggested by the growing number of PPI systems successfully
targeted by drug-like compounds, and the recent progress of two
PPI drugs to clinical testing in humans[8]. Although a vast array of
high-throughput, fragment-based and in vitro/in silico screening
technologies have been developed over the last 15 years [9], the
time and cost to chart PPI networks using these approaches
frighten any corporate decision board or government funding
body. Identification of PPI modulators is definitively challenging
[3,5–6,10–11] due to the plasticity of some interfaces but most
importantly to the unbalance between today’s screening libraries
and PPI inhibitors’ chemical spaces [4,12–18]. Hence, a possible
avenue to minimize the biomolecular or in silico screening burden
that is required to successfully target PPIs, is to design focused
libraries enriched in PPI inhibitors to realign the chemical space
window of compound collections with the chemical requirements
of PPI inhibitors. This approach should not only reduce wastes by
eliminating a priori compounds that are unlikely to impede/
modulate protein-protein complex formations but also lead to
enhanced potency or specificity of the binders. The focused library
concept [19] used on regular targets (e.g enzymes, GPCRs) has
however to be tailored to the singularity of PPIs. We advocate that
a possible solution to this conundrum is to mine relevant drug-like
PPI inhibitors and define a dedicated profile through the use
of appropriate chemoinformatics and machine learning tools.
Indeed, previous reports [3,20–23] have highlighted certain
‘‘universal’’ physico-chemical features of PPI inhibitors, i.e., our
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present understanding is that the molecules tend to be larger
than regular catalytic site inhibitors, they tend to be relatively
hydrophobic and rigid while often containing aromatic groups
[3,21–24], suggesting that it should be possible to apply machine-
learning and chemoinformatics methodologies on these molecules
together with key molecular descriptors to design a PPI inhibitor
profile and some PPI-inhibitor focused libraries [25–27]. Never-
theless, there is still some debate about whether such profile could or
should be global (i.e PPI-independent) or target-specific (like for
GPCRs or kinases). While it is clear that a global filter can not
reduce the size of the initial collection as much as a target-specific
filter, it has important advantages in the early discovery stages on
this difficult target class (i.e., for many PPIs there are neither known
small molecule inhibitors nor 3D structures to focus the collection in
a conventional target-specific manner).
In the present study, we selected appropriate Dragon’s molecular
descriptors[28] on a learning data set composed of true PPI
inhibitors and non-PPI inhibitors. We then ventured to build
machine learning-based computer models able to predict a global
and target-independent PPI inhibitor profile and transposed it into a
computer program, PPI-HitProfiler. We applied our tool to focus
several commercial compound collections to probe the concept and
assess the level of size reduction of those databases. Most
importantly, our program was further challenged on the experi-
mental screening results of 10 PPIs downloaded from the PubChem
Bioassay server. In addition, we carried out the in vitro screening of
two chemical library subsets on the p53/MDM2 interaction within
our CDithem drug discovery platform. Collectively, these experi-
mental results confirm the robustness of our tool, which managed to
discard more than half of the non-PPI inhibitors while identifying
70% of the true PPI inhibitors on those systems.
Results/Discussion
Construction of a machine-learning model to profile PPI
inhibitors
We used a chemical fingerprint-based clustering approach to
construct a chemically diversified learning data set ultimately
composed of 66 validated drug-like PPI inhibitors (Figure S1)
selected from the literature and of 557 non-PPI inhibitors obtained
from the ‘‘small molecule’’ subset of the DrugBank [29]. This
latter subset was chosen because historically it contains very few (if
any) PPI inhibitors, and therefore represents a valuable pool of
non-PPI inhibitors. Indeed, only 7 compounds on the whole
DrugBank small subset (4857 compounds) had a Tanimoto index
above 0.8 with one of the 66 PPI inhibitors. Further, to evaluate
the level of physico-chemical overlap between PPI and non-PPI
inhibitors, we ran a Principal Component Analysis (PCA) using
key descriptors (referred to as physico-chemical PCA), namely
molecular weight, octanol/water partition coefficient, topological
polar surface area, number of Hydrogen-bond donors and
acceptors, number of rotatable bonds and number of rigid bonds
(Figure 1). The subspace spanned by the first two principal
components (which account for more than 60% of the total
variance of the global physico-chemical space) are comparable for
PPI and non-PPI inhibitors on the learning data set (comparable
range and variability). The coverage of the protein space
corresponding to the 66 PPI inhibitors was also evaluated by
considering the SCOP fold classes of the associated PPIs. The 66
PPI inhibitors span over 27 different PPIs and 21 different SCOP
fold classes including various topological properties: mainly helix-
based domain; mainly beta-strand domain; mix folding (helix +
beta strand); and loop-binding groove domains (Figure S2).
On this learning data set, we initially computed the 1,666
Dragon molecular descriptors of E-Dragon (Dragon web version,
http://www.vcclab.org/lab/edragon/), but eventually kept only
the 357 most informative descriptors, were tested to construct
several machine-learning methods, such as, Decision Trees (DT)
and Support Vector Machines (SVM). The parameters of the
learning models were optimized using a cross validation protocol
such as to provide the best balance between enrichment (EF),
sensitivity (Se) and specificity (Sp) on the learning data set. We
then assessed these models on an independent validation data
set (Figure S3), composed of 26 other PPI inhibitors (that were
not present in the learning data set of 66 PPI inhibitors) and
2,000 decoys taken from the ChemBridge diversity set (www.
chembridge.com). The 26 PPI inhibitors span over 5 different PPI
and 5 different SCOP fold classes (Figure S4). Similarly to the
analysis performed on the learning data set, the physico-chemical
PCA ran on the PPI- and non-PPI inhibitors showed a fair overlap
of the physico-chemical subspaces associated to the two first
principal components (Figure 1).
From a methodological standpoint, we first observed that the
selected machine learning techniques could be successfully applied
to define/confirm a PPI inhibitor profile on the learning data set
(Table 1). Clearly, all SVM kernels were very efficient at
predicting the PPI inhibitor profile on the learning data set, with
a sensitivity of 92% and a specificity of 100% in the case of the
optimized sigmoid kernel. The two best DTs (1 and 2) also
performed well on the learning data set with sensitivities of 85 and
76% and specificities of 70 and 77%, respectively.
Nonetheless, we have mostly considered the performances of the
models on the validation data set (26 PPI inhibitors +2000 decoys),
which conceptually represents a real-life assessment of the models.
As seen on Table 1, the quality of the SVM-model predictions
could not be maintained neither during the 10-fold cross
validation (10-FCV) on the learning data set nor with the
validation data set as shown by the obtained sensitivity, specificity
and enrichment values. This clearly demonstrates an over training
of the SVM models on the learning data set, regardless of the
kernel used, and despite the cross validation-based optimization of
the SVM parameters. On the contrary, D.T.1 and D.T.2 display
Author Summary
Protein-protein interactions (PPIs) are essential to life and
various diseases states are associated with aberrant PPIs.
Therefore significant efforts are dedicated to this new class
of therapeutic targets. Even though it might not be
possible to modulate the estimated 650,000 PPIs that
regulate human life with drug-like compounds, a sizeable
number of PPI should be druggable. Only 10-15% of the
human genome is thought to be druggable with around
1000-3000 druggable protein targets. A hypothetical
similar ratio for PPIs would bring the number of druggable
PPIs to about 65,000, although no data can yet support
such a hypothesis. PPI have been historically intricate to
tackle with standard experimental and virtual screening
techniques, possibly because of the shift in the chemical
space between today’s chemical libraries and PPI physico-
chemical requirements. Therefore, one possible avenue to
circumvent this conundrum is to design focused libraries
enriched in putative PPI inhibitors. Here, we show how
chemoinformatics can assist library design by learning
physico-chemical rules from a data set of known PPI
inhibitors and their comparison with regular drugs. Our
study shows the importance of specific molecular shapes
and a privileged number of aromatic bonds.
Understanding Chemical Space of PPI Inhibitors
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more robust performances on the validation data set, with D.T.1
showing a sensitivity of 81% and a specificity of 70%, and D.T.
Nu2 showing a lower Se (70%) but a higher Sp (80.1%). These
results show that in this application decision trees outperform
support vector machines in predicting a PPI inhibitor profile on
our independent validation data set. This behavior also brings
the net advantage to provide the medicinal chemists with a
comprehensive description of the relevant physico-chemical
features required in the design or selection of PPI inhibitors.
Indeed, decision trees can offer a significant advantage over SVM
models, which result from the combination and transformation of
all the descriptors and usually lack interpretability. In the present
case, two decision trees were constructed in order to propose two
ways of balancing specificity and sensitivity. The two best DTs
were constructed with the two same Dragon descriptors,
RDF070m and UI, though with different thresholds for Ui
($3.95 and $4.13) (Figure 2). We observed a poor correlation
between RDF070m and Ui (r2RDF070m:UI = 0.34), which confirms
that they provide low redundancy and good complementarities in
discriminating PPI- from non-PPI inhibitors (Figure 3). RDF070m
is a Radial Distribution Function (RDF(r)) descriptor weighted by
the atomic masses using a sphere radius r of 7 A˚ as the associated
probability distribution function, and Ui is the unsaturation index,
directly correlated to the number of multiple bonds (double, triple
and aromatic bonds).
RDF(r) descriptors are known as shape descriptors. They
represent a radial distribution function of an ensemble of N atoms
and can be interpreted as the probability distribution to find an
atom in a spherical volume radius r:
RDF (r)~f
XN{1
i
XN
jwi
AiAje
{B(r{rij )
2
where f is a scaling factor, N is the total number of atoms, Ai and Aj
are atomic properties associated with the atom i and j whose
distance is defined by rij. B is a smoothing factor. f and B were set
to 0.007 and 100 A˚22 respectively. Ai and Aj, are in the case of
RDF070m, the atomic weight of atom i and j, respectively. This
family of descriptors is usually used as a multiple-value code
calculated at different discrete distances (here we just use r = 7 A˚)
and can be weighted by various atomic properties, here the atomic
Figure 1. Principal Component Analysis (PCA) on the learning and validation data sets. The calculations were run using 7 physico-
chemical, molecular weight, octanol/water partition coefficient, topological polar surface area, number of Hydrogen bond donors and acceptors, the
number of rotatable bonds and the number of rigid bonds. PPI inhibitors are represented as red disks, and non-PPI inhibitors are represented as black
circles.
doi:10.1371/journal.pcbi.1000695.g001
Table 1. Prediction results of the five best machine-learning
models.
Parameters Data set Se (%) Sp (%) EF
D.T.1 Learning 85 70 2.38
D.T.1 Validation 81 66 2.53
D.T.2 Learning 76 77 2.61
D.T.2 Validation 70 80 3.39
SVM Gaussian Kernel Learning 89 100 9.44
SVM Gaussian Kernel 10-FCV 39 97 5.71
SVM Gaussian Kernel Validation 33 85 2.23
SVM Sigmoid Kernel Learning 92 100 9.29
SVM Sigmoid Kernel 10-FCV 42 93 3.83
SVM Sigmoid Kernel Validation 33 81 1.77
SVM Polynomial Kernel Learning 89 100 9.44
SVM Polynomial Kernel 10-FCV 33 98 5.77
SVM Polynomial Kernel Validation 27 84 1.67
Representation of the different optimized machine learning models, two
decision trees, and three SVM models. Se (sensitivity), Sp (specificity) and EF
(Enrichment) values are given for both, the learning data set (66 PPI inhibitors
+557 non-PPI inhibitors) and the validation data set (26 PPI inhibitors +2,000
non-PPI inhibitors). (10-FCV= 10-Fold Cross Validation).
doi:10.1371/journal.pcbi.1000695.t001
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weight, but it can be partial charges, polarizability, etc. These
descriptors were successfully used to study active compounds on
Vitamin D receptor [30], flavonoid compounds as inhibitors of
aldose reductase [31] but more interestingly to predict 3D structures
from their infra red spectra in which specific substructures are by
definition associated to a specific signal, like the presence or absence
of multiple bonds in a given region of the compounds [32–33].
To illustrate the connection between the RDF070m descriptor
and the molecular shape, we calculated the RDF070m values for 4
co-crystallized synthetic inhibitors taken from 4 different PPI
complexes (1 protein of the PPI+1 synthetic inhibitor), namely
ICAM1/LFA, IL-2/IL-2Ra, p53/MDM2, and Xiap-BIR3/smac
complexes. We further calculated the values of RDF070m on 4
experimentally identified PPI inhibitors and 4 inactive com-
pounds, all 8 taken from the screening of the PPI CBFb/CBFa
interaction (PubChem Bioassay AID1434) (Figure 4). It is clear on
Figure 4 that RDF070m tends to have higher values when the
molecules have more ramifications and/or are star-, L-, or T-
shaped. Conversely, I-shaped molecules have lower values. To
further stress the prevalence of specific shapes observed within PPI
inhibitors structures, we noticed that several of the p53/MDM2
inhibitors satisfying the ‘‘thumb-index-middle’’ finger-pharmaco-
phore[34] that were present in our validation data set (26 PPI
inhibitors) have also high values for RDF070m. It must be noted
that even though RDF070m correlated partially with the
molecular weight (MW), it is only true at lower MW (MW,400)
(Figure 5). But, the combined descriptor obtained by dividing
RDF070m by MW is still capable of significantly discriminating
PPI inhibitors (p-valueRDF070m/MW = 5.74e-08). This is particular-
ly important because RDF070m stands at the top of the DTs and
therefore operates on the full data set. This demonstrates the
information added by RDF070m to significantly separate the two
populations (PPI inhibitors and non-PPI inhibitors) even at
equivalent MW. Indeed, it can be seen on Figure 4 that even
smaller compounds can have relatively high RDF070m values.
The second yet unraveled descriptor, UI, depends exclusively
on the number of multiple bonds:
UI~log2 1zbð Þ
where, b~
P
bonds
pij{B is the multiple bond count, and pij
* is the
conventional bond order of the bond between atom i and atom j
(pij
* = 1 for single bonds, pij
* = 2 for double and aromatic bonds,
Figure 2. Representation of the two decision trees D.T.1 (panel a) and D.T.2 (panel b) on the learning data set (66 PPI inhibitors +
557 non-PPI inhibitors). The two decision trees share the same two descriptors RDF070m and UI. The two thresholds for RDF070m are identical
($13.31) for D.T.1 and D.T.2 while the UI thresholds are different, $3.95 and $4.13 respectively for D.T.1 and D.T.2. The values for the corresponding
sensitivity (Se) and specificity (Sp) are indicated for each DT.
doi:10.1371/journal.pcbi.1000695.g002
Figure 3. Correlation Plot between RDF070m and UI descrip-
tors. Plot calculated on the 623 molecules of the learning data set: 66
PPI-inhibitors (dark filled triangles) +557 non-PPI inhibitors (dark circles).
The two thresholds of the decision tree Nu1 are RDF070m.13.31 and
UI.3.95. This plot first highlights the poor correlation between
RDF070m and UI (r2 = 0.34). Secondly, this shows that most of the
PPI-inhibitors are either above the RDF070m threshold (13.31) or above
the UI threshold (3.95).
doi:10.1371/journal.pcbi.1000695.g003
Understanding Chemical Space of PPI Inhibitors
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pij
* = 3 for triple bonds), the summation being run over all B
bonds. One can see that for single bonds, the pij
* contribution
cancels out with the term B, therefore making Ui relying
exclusively on the pij
* contribution of the multiple bonds. An
example of the Ui calculation is given on Figure 6 with Aspirin.
With such definition, one notices that the two above optimized
thresholds associated with the two DTs (D.T.1UI-threshold$3.95,
D.T.2UI-threshold$4.13), although being float values, can be traced
back to a discrete number of privileged multiple bonds. Indeed, if
one considers the number of triple bonds as negligible, which is the
case with 0.1-0.6% of triple bonds on average on any given
database, the two Ui thresholds correspond to a number of 15 and
17 multiple bonds (double or aromatic) respectively. This can be
confirmed by the strong correlation observed between Ui and
more explicit descriptors such as the number of multiple bonds
(r2UI:nBM = 0.95), the number of aromatic bonds (r
2
UI:nAB = 0.92)
Figure 4. Effect of molecular shape on descriptor RDF070m. The RDF070m values have been calculated on 4 cocrystallized PPI inhibitors of
the following PPIs: ICAM1/LFA, IL-2/IL-2Ra, p53/MDM2, and BIR3-Xiap/Smac. All 4 values are above the DTs threshold 13.31. The UI values are also
indicated, as well as the planarity of the binding pocket (calculated from the PROTORP server, http://www.bioinformatics.sussex.ac.uk/protorp/). Also,
on the panel below the calculated RDF070m values for 4 experimentally identified inhibitors (cyan) and 4 inactive compounds (green) of the CBFb/
CBFa interaction taken from PubChemBioassay AID1434.
doi:10.1371/journal.pcbi.1000695.g004
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and to a minor extent to the number of benzene-like ring
(r2 UI:nBnz = 0.75), highlighting the importance of double and
aromatic bonds. This is also coherent with previous observa-
tions[3,6,24,34] about the more pronounced aromatic, hydropho-
bic and rigid character of PPI inhibitors.
By analyzing these results, we suggest that the two models
(D.T.1 and D.T.2) we built bring complementary performances in
terms of sensitivity and specificity. D.T.1 has a stronger ability to
identify true PPI inhibitors (SeD.T.1 = 81%, SeD.T.2 = 70%) while
D.T.2 has a higher level of discrimination towards non-PPI
inhibitors (SpD.T.1 = 66%, SpD.T.2 = 80.1%). Therefore, the first
tree would be more suited to operate on relatively small libraries
(1,000 – 50,000 compounds) to maximize the chance of keeping a
higher number of true PPI inhibitors, while the second tree will be
useful to shrink large compound collections (over 50,000
compounds) with a higher efficacy, while keeping up to 70% of
true PPI inhibitors.
Lastly, during the 20-fold cross validation (20-FCV) procedure
used to choose the best descriptors involved in the DTs, other
descriptors emerged, although much less frequenty than
RDF070m and Ui. The first descriptor, ATS8m, could be used
instead of RDF070m at the top of the tree (EF = 2.65, Se = 72.7%,
Sp = 77.9%) in a very small minority of the 20-FCV configurations
(2 times over 20). This descriptor is a Broto-Moreau’s autocorre-
lation coefficient weighted by the molecular weight like
RDF070m. It is based on a Dirac delta function center at an
inter-atomic distance of 8 A˚ as opposed to RDF070m that is
constructed in reference to an inter-atomic distance of 7 A˚.
Interestingly, RDF080m was found interesting for one case in the
20-FCV configurations (EF = 2.53, Se = 78.8%, Sp = 74.5%),
highlighting also an inter-atomic distance of 8 A˚. Concerning
the second node of the tree, the descriptor PCR, could be used
instead of Ui only on a minority of the 20-FCV configurations (2
over of 20)(EF = 2.33, Se = 77.3%, Sp = 72.0%), and correlated
with Ui (r2 = 0.802). This descriptor is a walk and path count
descriptor and more specifically the ratio of multiple path count
over path count descriptor. This descriptor is, as Ui, linked to the
ratio of multiple bonds with respect to the total number of bonds,
but was found poorly efficient to discriminate true PPI inhibitors
as compared to Ui.
Those results highlight the relevance and robustness of the
chosen descriptors, RDF070m and Ui. Indeed, even when these
descriptors were not retained as the very best ones (due to the
unavoidably subsampling bias of the 20-FCV procedure), the
alternative descriptors chosen brought a similar rather than
orthogonal description.
Implementation of the DTs into a computer program:
PPI-HitProfiler
We then developed a computer program, named PPI-
HitProfiler, to transpose our best DTs into a user-friendly
command line package that takes as input any drug-like chemical
library, calculates for each compound the two aforementioned
descriptors, determines whether the compound satisfies the
corresponding thresholds and generates a focused chemical
library enriched in putative PPI inhibitors. As seen above,
RDF070m and Ui are relatively simple descriptors to implement.
This has been done using the Python-Pybel package[35] which is
an object-oriented programming package allowing an easy
manipulation of small compounds and of their main atomic
properties.
Assessment of PPI-HitProfiler on size reduction with
commercial compound collections
To illustrate the benefit of using PPI-HitProfiler in terms of
reducing the chemical collection size, we applied it on a drug-like
version of the MayBridge Screening Collection (www.maybridge.
com) filtered with our ADMET tool FAF-Drugs2[36]. From the
57,200 molecules initially present in this library, 31,107 molecules
passed the soft ADMET filtering protocol. Subsequently, 17,162
molecules passed PPI-HitProfiler when using model D.T.1 and
13,799 for the model D.T.2 (Table 2). A similar evaluation carried
out on the diversity set of the ChemBridge database that initially
contained 50,000 compounds led to an intermediate library of
39,623 satisfying the ADMET filters and ultimately 12,866
compounds with PPI-HitProfiler-D.T.1 and 9,622 compounds
with PPI-HitProfiler-D.T.2 (Table 2). In this latter case, the use of
D.T.2 represents a size reduction of 76% from the ADMET
version of the ChemBridge diversity set, and of 81% from the
initial ChemBridge diversity set.
Figure 5. Correlation plot between RDF070m and MW on the
learning data set (66 PPI inhibitors (Red disks) +557 non-PPI
inhibitors (black circles)). This figure shows that correlations
between RDF070m and MW are significant only for compounds below
400. At higher MW, RDF070m performs better than MW.
doi:10.1371/journal.pcbi.1000695.g005
Figure 6. Calculation of UI on Aspirin. UiAspirin = 3.17: aspirin has a
total of 21 bonds, such that B=21, 13 single bonds that have a con-
tribution of 1 to b, and 8 double and aromatic bonds that have a
contribution of 2 to b, such that the multiple bond count b is equal to
b=13x1+8x2 - 21=8. Thus Ui= log2(1+b)= log2(1+8)=3.17.
doi:10.1371/journal.pcbi.1000695.g006
Understanding Chemical Space of PPI Inhibitors
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Assessment of PPI-HitProfiler using HTS results from
PubChem BioAssay
We then evaluated the performance of our PPI-HitProfiler on
the HTS results of 10 different PPIs taken from the PubChem
BioAssay server: BFL-1/Bid (AID432), CBFb/CBFa (AID1434),
EphA4/ephrin-A (AID689), Xiap/Bir1-2 (AID1018), MCL-1/
NOXA (AID1417) CD11b-CD18/Fibrinogen (AID1499), Hsp90/
TPR2A (AID595), BRCT/Phosphoprotein (AID875), TLR4/
MyD88 (AID811), Multiplex Bcl-2 family/Bim (AID1330). The
results show a robust behavior of our tool with an average of 81%
and 70% of correctly predicted PPI inhibitors and 42% and 52%
of the inactive compounds removed from the initial collections
when using PPI-HitProfiler-D.T.1 and –D.T.2, respectively. One
can see that the D.T.2 version of PPI-HitProfiler which has a
higher specificity and is therefore more appropriate for larger
chemical collection shows a robust behavior for the 3 PubChem
BioAssays having more than 50,000 compounds (AID1434,
AID1018, and AID1499) by predicting correctly from 70 to
84% of the true PPI inhibitors while steadily removing more than
half of the inactive compounds. On the other hand, for the
screening assays where the total number of compounds screened is
significantly below 50,000 i.e AID689, AID1417, AID811,
AID1330 and for the p53/MDM2 CDithem screening (see
below), one can see that the sensitivity is on average about 87%
even though the average specificity on these results (38.2%) is
slightly below the global average (42%). Interestingly, we noticed
that true PPI inhibitors being correctly selected were flagged by
the two descriptors RDF070m and UI in a 20:80 ratio highlighting
the importance of multiple bonds and especially aromatic bonds in
the specificity of PPI inhibitors. This further illustrates that PPI
inhibitors must have a specific molecular shape, or that they tend
to have a higher number of multiple bonds to compensate.
Similarly to what was done for the learning and validation data
set, the physico-chemical PCA that was carried out on each of the
AID data sets using the same 7 descriptors (Figure 7 and 8), shows
that the physico-chemical subspaces spanned by the first two
principal components (which account for about 60% of the
variance of the global physico-chemical space) are equivalent for
PPI and non-PPI inhibitors. This also means, mainly for the AIDs
having a large number of active compounds (AID1434, AID689,
AID1417, and AID595) for which it is easier to evaluate the level
of physico-chemical space overlap (Figure 7 and 8), that classical
descriptors (e.g higher MW and higher hydrophobicity, higher
rigidity) may be not be always sufficient to distinguish them from
inactive compounds. Rather, another way to embrace their key
properties without counteracting known facts may be the further
consideration of their molecular shape and aromaticity.
Finally, we also evaluated the coverage of protein space
corresponding to the validation data set and the various screening
results (AIDs). All combined, the validation of our tool spanned
over 15 different PPIs, 5 for the validation data set and 10 for the
different AID screening results. These correspond to 13 different
SCOP fold classes. As it can be seen on Table 3 those classes
include various types of folding including: mainly helix-based
folding; mainly-beta sheet-based folding; mix-folding (helix+beta
strand); and loop-binding groove systems.
Assessment of PPI-HitProfiler through the in vitro
screening of p53/MDM2
We then challenged our PPI-HitProfiler through the in vitro
screening of the p53/MDM2 complex. The p53 tumor suppressor
is vital in cell cycle regulation DNA repair, and apoptosis[37–38].
Its implication has been observed in all human cancers either with
mutations or through a pure inhibition due to an overexpression of
its native partner, murine double minute 2 oncoprotein (MDM2).
This PPI has therefore been the subject of numerous experimental
screening studies yielding to the development of several synthetic
PPI inhibitors [39–43]. Using a fluorescence polarization assay
within our CDithem platform to monitor the p53/MDM2
interaction, we screened a total of 4,705 drug-like compounds
filtered from Asinex (3,400 cpmds) (www.asinex.com) and
ChemDiv (2,400 cpmds) (www.chemdiv.com) subsets using FAF-
Drugs2. The experimental screening led to the identification of 4
new inhibitors of the p53/MDM2 interaction with pIC50 ranging
from 4.6 to 5.5 (Figure 9). Interestingly, 3 out of those 4 new
inhibitors (Se = 75%) passed our two filters (PPI-HitProfiler-D.T.1
and PPI-HitProfiler-D.T.2). Compound BDM_4605 (pIC50 = 4.6)
was missed by both our filters because it has a low RDF070m
value (3.11) far from the threshold (set at 13.31) at the top of the
trees, and a low Ui value as well (3.907) when a minimal of 3.95 is
required to pass at least the threshold of D.T.1. Interestingly, this
represents only 14 multiple bonds (double and aromatic) when 15
are required for D.T.1. Among the three correctly detected
compounds all passed by the most stringent threshold for Ui (4.13),
which represents the presence of at least 17 multiple bonds.
Compound BDM_26 also passed the RDF070m threshold with a
value of 20.31. In this case again, one can see the star-like structure
of the compound, which contributes to most of the high value of
RDF070m in a similar manner to the well known structure of the
Nutlin compounds (e.g compound 2 in Figure S1) that are also
active on p53/MDM2. Conversely, from the 4,705 compounds
tested, PPI-HitProfiler-D.T.1 managed to remove 32% of the
inactive compounds (Sp = 32%) on this PPI system whereas PPI-
HitProfiler-D.T.2 removed 43% (Sp = 43%) of the initial screened
collection (Table 3). These results showed that used prior to
experimental screening PPI-HitProfiler-D.T.2 would manage to
identify 75% of the true PPI inhibitors on p53/MDM2 while
nearly dividing in half the initial compound collection. As for the
learning data set, the results of a physico-chemical PCA carried
out on these screening results using the 7 descriptors cited above
Table 2. Effect of PPI-HitProfiler on the size of two commercial collections.
MayBridge Screening Collection 57,200 Compounds ChemBridge Diversity Set 50,000 Compounds
ADMET filter 31,107 Compounds ADMET filter 39,623 Compounds
PPI-HitProfiler-D.T.1
17,162 Compounds
PPI-HitProfiler-D.T.2
13,799 Compounds
PPI-HitProfiler-D.T.1
12,866 Compounds
PPI-HitProfiler-D.T.2
9,622 Compounds
45% 56% 68% 76%
The two collections were filtered with FAFDrugs2 for ADMET properties, and the resulting drug-like databases were profiled using PPI-HitProfiler (D.T.1 and D.T.2
versions) to estimate the size reduction. The percentage of reduction within the table is calculated with respect to the drug-like version of the collections.
doi:10.1371/journal.pcbi.1000695.t002
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Figure 7. Principal Component Analysis (PCA) on the various screening results (AID1434, AID689, AID1018, AID1417, AID432). The
calculations were run using 7 physico-chemical, molecular weight, octanol/water partition coefficient, topological polar surface area, number of
Hydrogen bond donors and acceptors, the number of rotatable bonds and the number of rigid bonds. PPI inhibitors are represented as red disks, and
non-PPI inhibitors are represented as black circles.
doi:10.1371/journal.pcbi.1000695.g007
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Figure 8. Principal Component Analysis (PCA) on the various screening results (AID1499, AID595, AID875, AID811, AID1330,
CDithem). The calculations were run using 7 physico-chemical, molecular weight, octanol/water partition coefficient, topological polar surface area,
number of Hydrogen bond donors and acceptors, the number of rotatable bonds and the number of rigid bonds. PPI inhibitors are represented as
red disks, and non-PPI inhibitors are represented as black circles.
doi:10.1371/journal.pcbi.1000695.g008
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Table 3. PPI-HitProfiler evaluation on HTS results.
Experiments Scop fold
Nb of inatives
TN + FP
Total Nb Hits
TP + FN
PPI-
HitProfiler TN TP
Sp
(%)
Se
(%) EF
AID432 BFL-1/Bid Toxins’ membrane
translocation domains.
Multi-helical domains
46 466 10 D.T 1 20045 8 43 80 1.41
AID432 BFL-1/Bid Toxins’ membrane
translocation domains.
Multi-helical domains
46 466 10 D.T 2 25073 7 54 70 1.52
AID1434 CBFb/CBFa Core binding factor beta.
Barrel; capped at both
ends by alpha-helices
117 533 894 D.T 1 48620 722 41 81 1.39
AID1434 CBFb/CBFa Core binding factor beta.
Barrel; capped at both
ends by alpha-helices
117 533 894 D.T 2 61889 621 53 70 1.48
AID689 EphA4/ephrin-A N/A Loop-binding groove 37 114 38 D.T 1 14684 33 40 87 1.44
AID689 EphA4/ephrin-A N/A Loop-binding groove 37 114 38 D.T 2 18481 27 50 71 1.42
AID1018 Xiap/Bir1-2 Inhibitor of apoptosis (IAP) repeat.
Metal(zinc)-bound alpha+beta fold
112 346 6 D.T 1 47084 5 42 84 1.43
AID1018 Xiap/Bir1-2 Inhibitor of apoptosis (IAP) repeat.
Metal(zinc)-bound alpha+beta fold
112 346 6 D.T 2 58187 5 52 84 1.73
AID1417 MCL-1/NOXA Toxins’ membrane
translocation domains.
Multi-helical domains
134 347 D.T 1 58 296 43 85 5.40
AID1417 MCL-1/NOXA Toxins’ membrane
translocation domains.
Multi-helical domains
134 347 D.T 2 71 243 53 70 5.35
AID1499 CD11b-CD18/
Fibrinogen
vWA-like.
Mixed beta-sheet of 6 strands
58 790 34 D.T 1 23924 28 41 82 1.39
AID1499 CD11b-CD18/
Fibrinogen
vWA-like.
Mixed beta-sheet of 6 strands
58 790 34 D.T 2 29694 28 51 82 1.66
AID595 Hsp90/TPR2A alpha-alpha superhelix.
Right-handed superhelix
46 519 174 D.T 1 19309 124 42 71 1.22
AID595 Hsp90/TPR2A alpha-alpha superhelix.
Right-handed superhelix
46 519 174 D.T 2 23613 112 51 64 1.31
AID875 BRCT/
Phosphoprotein
BRCT domain. Parallel.
beta-sheet of 4 strands
48 183 17 D.T 1 20259 15 42 88 1.52
AID875 BRCT/
Phosphoprotein
BRCT domain. Parallel.
beta-sheet of 4 strands
48 183 17 D.T 2 24709 11 51 65 1.33
AID811 TLR4/MyD88 Flavodoxin-like. parallel
beta-sheet of 5 strand
7 116 3 D.T 1 3502 3 49 100 1.97
AID811 TLR4/MyD88 Flavodoxin-like. parallel
beta-sheet of 5 strand
7 116 3 D.T 2 4295 3 60 100 2.52
AID1330 Multiplex
Bcl-2 family/Bim
Toxins’ membrane
translocation domains.
Multi-helical domains
461 14 D.T 1 125 13 27 92 1.31
AID1330 Multiplex
Bcl-2 family/Bim
Toxins’ membrane
translocation domains.
Multi-helical domains
461 14 D.T 2 181 11 39 79 1.33
CDithem Screening
p53/MDM2
SWIB/MDM2 domain.
4 helices; capped by two
small 3-stranded beta-sheets
4 705 4 D.T 1 1508 3 32 75 1.10
CDithem Screening
p53/MDM2
SWIB/MDM2 domain.
4 helices; capped by two
small 3-stranded beta-sheets
4 705 4 D.T 2 2003 3 43 75 1.31
All HTS cumulated D.T 1 199118 1 250 42 81 1.39
All HTS cumulated D.T 2 248196 1 071 52 70 1.45
Results of the application of PPI-HitProfiler on topologically diverse PubChem BioAssay results and on the CDithem screening of the p53/MDM2 interaction. All data sets
were previously filtered with FAF-Drugs2 using the same parameters as for the learning data set. The total number of inactive compounds (TN + FP). active compounds
(TP + FN). remaining inactives (TN). and remaining actives (TP). are used to calculate the sensitivity and specificity of PPI-HitProfiler on each data set.
TP: number of PPI inhibitors correctly classified.
FP: number of non-PPI inhibitors classified as PPI-inhibitors.
TN: number of non-PPI inhibitors correctly classified.
FN: number of PPI inhibitors classified as non-PPI inhibitors.
Sensitivity = TP/(TP + FN).
Specificity = TN/(TN + FP).
doi:10.1371/journal.pcbi.1000695.t003
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showed a fair overlap of the physico-chemical subspaces of the two
subpopulations (actives and inactives). We then used the p53/
MDM2 data set to assess the applicability domain of PPI-
HitProfiler. We ran another principal component analysis (PCA)
on the 623 molecules of the learning data set and the 357 E-
Dragon descriptors that remained for the construction and
optimization of the decision trees. The 3 first axis of the PCA
were used to plot the molecules of the two subsets screened (Asinex
+ ChemDiv) in the flurorescence polarization assay (Figure 10).
Even though the 3 first axis of the PCA represent only 40% of the
global variance, these results tend to show that the screened
collection stood within the domain of applicability of PPI-
HitProfiler.
Conclusion
In summary, we suggest that it may be possible to determine a
global PPI inhibitor profile having appropriate ADMET proper-
ties using machine-learning techniques. Descriptor-based decision
trees managed to positively discriminate PPI inhibitors combining
only two molecular descriptors, RDF070m and Ui, which
respectively describe specific ramified molecular shape and the
presence of 15–17 multiple bonds in the compound. The
development of a new computer package named PPI-HitProfiler
allows the design of focused libraries enriched in PPI inhibitors
starting from any drug-like compound collection. Its applications
on two commercial compound collections, and its assessment on
the experimental screening results of 11 different PPI systems
shows a robust behavior in identifying true PPI inhibitors, from 70
to 81%, and its capacity to discard putative non-PPI inhibitors,
from 42 to 52%, depending on the version of PPI-HitProfiler used.
Although, removing 52% of inactive compounds from a chemical
collection might seem rather low when designing focused chemical
libraries, it has to be kept in mind that PPIs are a large and very
diverse family. Futhermore, lead discovery in the pharmaceutical
environment is at an industrial scale in which it is typical to screen
1–5 million compounds in few weeks using HTS. Yet the financial
cost of an HTS campaign of 1 million compounds is anywhere
between $500 000 to $1000 000[13]. This means in this case a cost
saving from $260 000 to $2 600 000 pet target. Clearly, some
potentially interesting compounds could be lost after any type of
filtering but the next blockbuster can also be missed by any kind of
experimental high-throughput methods. Moreover, at present no
one can foresee to what extent one can reduce the initial size of
screening collections using a global and target-independent PPI
Figure 9. 2D sketch of the 4 new inhibitors of the p53/MDM2 interaction identified by our CDithem fluorescence polarization assay
along with their potency (pIC50) and their RDF070m and UI values.
doi:10.1371/journal.pcbi.1000695.g009
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inhibitor profiler like the one presented herein. This really depends
on the quality of the initial collection as suggests the difference in
specificity between PubChem BioAssay databases, and the
ChemBridge and MayBridge collections.
One avenue to circumvent this problem should be to design PPI-
specific profiler that would take into account topology and types of
interactions, e.g a-helix bound to a groove (p53/MDM2), or inter-
protein beta-sheet (Xiap-BIR3/Smac), etc. This way, more speci-
ficity could be brought to the statistical models. One can imagine to
design focused libraries by applying successive filters from the most
global, like PPI-HitProfiler, to the more specific that could represent
only a precise type of protein-protein interaction.
At this stage of development and present knowledge, we
strongly believe that ‘‘target-independent’’ PPI inhibitor profiler
can be successfully applied prior to in silico or in vitro screening
experiments not only for drug discovery projects to avoid a full-
scale screening but also for chemical biology projects. Because it is
known that target selection is a major bottleneck in today’s drug
discovery endeavors and that targets are nowadays less validated
than in the nineties [44], time and cost-effective in silico
technologies could here assist achieving systematic success in spite
of the present global economic downturn.
Methods
Data set preparation: learning and validation data sets
145 PPI inhibitors identified by both in vitro and in vivo
experiments were taken from the literature and ADMET filtered
with our program FAF-Drugs2[36] using very soft parameters for
both physico-chemical properties and presence of toxic/reactive
groups.
(100,MW,900; 0,HBD,8; 0,HBA = 12; -5,XLogP,6;
0,nROT,20; 0,TPSA,160; +one allowed Lipinski’s rule
violation). The remaining 81 PPI inhibitors were clustered with
the program LigandInfo[45] using a hierarchical normal ascending
classification with a diversity criterion of 0.8. From this classification
Figure 10. Applicability domain of PPI-HitProfiler. The application domain of PPI-HitProfiler has been evaluated using a Principal Component
Analysis (PCA) on the 623 molecules of the learning data (red) set and the 357 initial E-Dragon descriptors that were used to construct the decision
trees. The graph represents the 3 first axis of the PCA (40% of the variance) which have been used to calculate the coordinates of the 1,645 molecules
of the ChemDiv subset (green) and the 3,060 molecules of the Asinex Subset (blue). A good overlap between the three subsets (Red, Green, and Blue)
can be observed which indicates that the molecules from the Asinex and ChemDiv subsets stand within the applicability domain of PPI-HitProfiler
and that the focused library resulting from the two subsets is meaningful.
doi:10.1371/journal.pcbi.1000695.g010
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one representative molecule from each cluster was taken such as
having ultimately 66 structurally diverse PPI inhibitors (Figure S1).
These compounds were used as the positive learning data set. A
similar protocol was applied to define a negative learning data set.
To do so, the 4,857 molecules from the ‘‘small molecules’’ subset of
the DrugBank database were used. The small subset of the
DrugBank contained for example 5% of compounds with a MW
higher than 900. Moreover, not all the drugs from this subset have
an orally bioavailable profile. All those molecules were therefore
filtered using the same ADMET parameters. For historical reasons
the small subset of the Drugbank contains very few PPI inhibitors.
There are only 7 compounds from the whole ‘‘small subset’’ of the
Drugbank that have a Tanimoto index above 0.8 with one of the 66
PPI inhibitors.
The ADME/tox filtering step selected 942 molecules that were
clustered as above leading to a diversity set of 557 drug-like
molecules. Ultimately, the learning data set contained 66 true PPI
inhibitors, 557 non-PPI inhibitors and 623 molecules in total. An
independent validation set was constructed to assess the robustness of
the model. It contained 26 different PPI inhibitors (Figure S2) and
2,000 molecules from the ChemBridge diversity set filtered as above.
More specifically, only two compounds from the 26 PPI inhibitors of
the validation dataset had a Tanimoto indice with one of the 66
(learning dataset) PPI inhibitors comprised between 0.8 and 0.9. Very
few of them came from the initial pool of 145 PPI inhibitors (3 of
them). Two compounds had a Tanimoto index between 0.8 and 1.0
with of the 145 PPI inhibitors but the vast majority were some
different extra compounds.
Data set preparation: remaining data sets
The ADMET parameters used above for the filtering of the
learning and validating data sets have also been used on the
MayBridge and ChemBridge screening collections, as well as on
the collections that were experimentally screened in the 10 PubChem
BioAssays and in our fluorescence polarization assay on the p53/
MDM2 interaction.
Definition of enrichment, sensitivity and specificity
TP: number of PPI inhibitors correctly classified
FP: number of non-PPI inhibitors uncorrectly classified as
PPI-inhibitors
TN: number of non-PPI inhibitors correctly classified
FN: number of PPI inhibitors uncorrectly classified as non-PPI
inhibitors
EF: Enrichment factor
EF~
TP
TPzFPð Þ 
TPzFPzTNzFNð Þ
TPzFNð Þ
Se~Sensitivity~TP= TPzFNð Þ
Sp~Specificity~TN TNzFPð Þ
Statistical analysis: molecular descriptor calculation and
preprocessing
Descriptors were calculated by the program E-DRAGON, a
web-server based version of DRAGON[28] (version 5.4) contain-
ing 1,666 descriptors.
The protocol described herein was used to eliminate non-
relevant descriptors on the learning data set. Descriptors whose
variance was zero (discard 108 descriptors), gathered descriptors
according to correlation coefficient above 0.9 (discard 936
descriptors), descriptors whose Student T-test p-value was above
0.2 between the positive and negative learning data sets (discard
265 descriptors), such that 357 descriptors were initially retained to
perform our computations.
Learning methods
Support vector machines. Support vector machines belong
to the class of machine learning algorithms that has recently
become prominent in both computational biology and chemistry.
This method implicitly embeds the data of interest in a high-
dimensional feature space where classification or regression can be
more easily performed with linear rules than in the original
descriptor space. In SVM, a hyperplane maximizing its distance to
the nearest observations (in the new space) is chosen. The
optimization of parameters was processed by 10-fold cross
validation (10-FCV) and factorial design. Three well-established
and diverse kernels were tested: gaussian, sigmoid and polynomial.
The best combination of parameters was chosen by monitoring
enrichment, sensitivity and specificity from 10-FCV results
(Table 4).
Decision trees. Decision trees were constructed by analyzing
a set of training samples for which the class labels were known. At
each node, they recursively binary partition the data according to
a threshold applied on one descriptor value. If trained on high-
quality data, decision trees can make very accurate predictions. In
this study, the decision tree was optimized with a cross validation
protocol and manually edited. Instead of the classical indexes
usually used for evaluating the quality of decision trees (such as
entropy or Gini index), the trees were optimized such as providing
the best global enrichment, which in this specific case provides a
more suitable evaluation. The decision tree was built as follow. At
each node, the descriptor whose best threshold value led to the
best enrichment was chosen to become the local node. The
construction was stopped when less than five observations were
found in a leaf. Twenty trees were constructed by 20-fold cross
validation. The choice of the final trees was motivated by only
keeping nodes using the same descriptor for most of the trees. The
final corresponding threshold was assigned to the modal value.
p53/MDM2 interaction: Fluorescence Polarization Assay
(FPA)
We chose a 9-mer peptide from p53, a fragment known to be
sufficient to assess the p53/MDM2 interaction. The 9-mer p53
sequence-derived 5-carboxyfluorescein-labeled peptide (5FAM-
RFMDYWEGL, Parks et al., 2005) was synthesized by AnaSpec
(San Jose, CA, USA).
Full length MDM2 was subcloned into the expression plasmid
pET28a (Novagen, Darmstadt, Germany) using standard methods.
Table 4. SVM optimized parameters.
Kernel C
Kernel
Scale
Kernel
offset
Kernel
degree
Gaussian 10 1023
Sigmoid 103 1024 1023
Polynomial 10 1023 1 2
doi:10.1371/journal.pcbi.1000695.t004
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Following protein expression in Escherichia coli BL21 (DE3)
(Invitrogen, Carlsbad, CA, USA), bacterial cells were harvested
by centrifugation followed by resuspension in 50 mM Tris-HCl
(pH 8.0), 200 mM NaCl, 5 mM Imidazole, 0.1% triton X-100,
protease inhibitor mixture EDTA-free (Roche Applied Science,
Rotkreuz, Switzerland) at 4uC, and lysed by sonication. After
centrifugation at 13000 rpm 10 min at 4uC, soluble His-tagged
proteins were purified using Ni-NTA agarose beads according to
the manufacturer procedures (Qiagen, Valencia, CA).
Fractions containing MDM2 proteins were pooled, dialysed into
20 mM Tris-HCl (pH 8.0), 100 mM KCl, 1 mM DTT, 0.2 mM
EDTA, 0.05% triton X-100, 20% glycerol, frozen in liquid
nitrogen, and kept at -80uC for further experiments.
FP assays were performed in black low-binding surface 96-well
plates (Corning, NY), in a total volume of 75 mL PBS, containing
10 nM of the 5FAM-labeled peptide, 18 nM of purified MDM2,
30 mM of compound to be tested, and 3% DMSO. MDM2 was
allowed to incubate with the compounds 10 min prior to adding
the 5FAM-labeled peptide. After 5 minutes, FP measurements
were performed on a Victor 3V plate reader (Wallac, Turku,
Finland) using a 485 nm excitation filter, a 535 nm emission filter,
and a 0.2 s per well reading time.
Supporting Information
Figure S1 Chemical structures of the 66 selected PPI inhibitors
used as the positive learning data set.
Found at: doi:10.1371/journal.pcbi.1000695.s001 (1.86 MB TIF)
Figure S2 Description of the protein space coverage of the 66
PPI inhibitors of the learning data set in term SCOP fold classes.
The validation data set covers 27 different PPI and 21 pairs of
SCOP fold classes.
Found at: doi:10.1371/journal.pcbi.1000695.s002 (0.04 MB PDF)
Figure S3 Chemical structures of the 26 selected PPI inhibitors
used as the positive validation data set.
Found at: doi:10.1371/journal.pcbi.1000695.s003 (0.21 MB TIF)
Figure S4 Description of the protein space coverage of the 26 PPI
inhibitors of the learning data set in term SCOP fold classes. The
validation data set covers 5 different PPI and 5 pairs of SCOP fold
classes.
Found at: doi:10.1371/journal.pcbi.1000695.s004 (0.02 MB PDF)
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